news

Cyril Amarchand Mangaldas and AZB & Partners have guided the division of India’s Godrej conglomerate between two branches of the Godrej family, with Adi Godrej and Nadir Godrej-led side represented by CAM and the Jamshyd Godrej and Smita Godrej Crishna-led branch advised by AZB.

The Godrej family has agreed to restructure its shareholding in the conglomerate into two entities: Jamshyd Godrej-led Godrej Enterprises Group (GEG) and Adi Godrej-led Godrej Industries Group (GIG).

The CAM team on the settlement was led by managing partner Cyril Shroff, along with private client practice co-head Rishabh Shroff, and corporate partner Ramgovind Kuruppath. Principal associate Archit Bhatnagar and senior associates Surabhi Saboo and Nikita Singhi also assisted on the deal.

Competition head Avaantika Kakkar assisted with the antitrust aspects of the deal, while corporate partner Aditya Prasad advised on open offer-related aspects.

The AZB team on the deal was led by managing partner Zia Mody.

The realignment will be implemented after the relevant regulatory approvals have been obtained, after which the two companies will continue to use the Godrej brand, Reuters reported.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

CAM, WFW act on $185 mln Adani Ports acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas advised its longstanding client Adani on Adani Ports and Special Economic Zone’s acquisition of 80 percent stake in Astro Offshore, an offshore support vessel operator. Watson Farley & Williams advised the selling shareholders of Astro Offshore.

Anagram adds M&A and PE partner from IndusLaw

by Nimitt Dixit |

M&A-focused Anagram Partners has become the latest to turn to IndusLaw to expand its offerings with the addition of M&A and private equity-focused partner Faraz Khan in Mumbai.

Trilegal, Latham, Quillon act on Platinum Equity’s India PE debut

by Nimitt Dixit |

Trilegal and Latham & Watkins have advised U.S.-based buyout fund Platinum Equity on its debut private equity deal in India, in the form of the acquisition of a majority stake in Inventia Healthcare, a Mumbai-based pharmaceutical company, at a valuation of $300 million.